Akero Therapeutics
AKRO
AKRO was delisted on the 8th of December, 2025.
109 hedge funds and large institutions have $913M invested in Akero Therapeutics in 2021 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 29 increasing their positions, 31 reducing their positions, and 9 closing their positions.
167% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 9
16% more funds holding
Funds holding: 94 → 109 (+15)
12% more capital invested
Capital invested by funds: $814M → $913M (+$99.7M)
1.78% more ownership
Funds ownership: 88.84% → 90.62% (+1.8%)
6% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 31
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
91% less call options, than puts
Call options by funds: $2.23M | Put options by funds: $24.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YCM
Yiheng Capital Management
San Francisco,
California
|
+$8.12M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$7.13M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$6.32M |
| 4 |
Alkeon Capital Management
New York
|
+$6.3M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$5.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.01M |
| 2 |
Millennium Management
New York
|
-$5.42M |
| 3 |
VVM
Versant Venture Management
San Francisco,
California
|
-$4.84M |
| 4 |
Renaissance Technologies
New York
|
-$3.87M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.85M |
AKRO Hedge Fund Activity: Q1 2021 in Review
109 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q1 2021, worth a combined $913M — up 12% from $814M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new AKRO positions and 9 closed out — a net gain of 15 holders — while 29 added to existing stakes and 31 trimmed.
The largest buyer was Yiheng Capital Management, opening a new position worth an estimated $8.12M. The largest seller was Point72 Asset Management, cutting an estimated $6.01M.
- 109 institutional investors held Akero Therapeutics (AKRO) as of Q1 2021, up from 94 in Q4 2020.
- Funds reported $913M of Akero Therapeutics stock for Q1 2021, up 12% quarter-over-quarter.
- 24 funds opened new Akero Therapeutics positions in Q1 2021 and 9 closed out, a net change of +15 holders.
- The largest Akero Therapeutics buyer in Q1 2021 was Yiheng Capital Management, an estimated $8.12M added.
- The largest Akero Therapeutics seller in Q1 2021 was Point72 Asset Management, an estimated $6.01M sold.
Based on aggregated 13F filings for Q1 2021.